Esperion to pay $75M upfront for Corstasis, taps $4B U.S. diuretic market
Esperion will acquire Corstasis for $75 million upfront and up to $180 million in royalties and milestones to integrate Enbumyst, the first FDA-approved nasal spray diuretic for heart failure edema. With $92.4 million in cash and planned Q2 2026 closing, Esperion targets a U.S. diuretic market exceeding $4 billion.
1. Acquisition Details
Esperion has entered into a definitive agreement to acquire Corstasis Therapeutics, the developer of Enbumyst, the first FDA-approved nasal spray diuretic indicated for edema associated with congestive heart failure.
2. Deal Financing and Payments
The transaction includes a $75 million upfront cash payment plus potential royalties and milestone payments totaling up to $180 million, funded through existing credit facilities and royalty monetization of Japanese royalties. Esperion held $92.4 million in cash and equivalents as of September 30, 2025.
3. Strategic Rationale and Market Opportunity
Esperion aims to leverage its cardiovascular commercial infrastructure to integrate Enbumyst and capture a U.S. diuretic market opportunity exceeding $4 billion, targeting sustained double-digit revenue growth and enhanced portfolio diversification.
4. Expected Closing Timeline
The acquisition is expected to close in the second quarter of 2026, positioning Enbumyst for integration ahead of Esperion's fiscal plans and upcoming March 10 earnings report.